Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
Ligand's Technologies Support and Enable Potential Coronavirus Treatments
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th
Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
